OBJECTIVE

To evaluate glycemic outcomes in youth (aged 13–25 years) with type 1 diabetes and high-risk glycemic control (HbA1c ≥8.5% [69 mmol/mol]) on multiple daily injection (MDI) therapy after transitioning to advanced hybrid closed loop (AHCL) therapy.

RESEARCH DESIGN AND METHODS

This prospective, 3-month, single-arm, dual-center study enrolled 20 participants, and all completed the study.

RESULTS

HbA1c decreased from 10.5 ± 2.1% (91.2 ± 22.8 mmol/mol) at baseline to 7.6 ± 1.1% (59.7 ± 11.9 mmol/mol), and time spent in target range 70–180 mg/dL (3.9–10.0 mmol/L) increased from 27.6 ± 13.2% at baseline to 66.5 ± 9.8% after 3 months of AHCL. Two episodes of diabetic ketoacidosis attributed to infusion set failure occurred.

CONCLUSIONS

AHCL has the potential to improve suboptimal glycemia in youth with type 1 diabetes previously on MDI therapy.

Clinical trial reg. no. ACTRN12621000556842, www.anzctr.org.au

This article contains supplementary material online at https://doi.org/10.2337/figshare.21785207.

This content is only available via PDF.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/journals/pages/license.
You do not currently have access to this content.